title: Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.
abstract: In order to establish an efficient gammadelta T cell-mediated immunotherapy for hematological malignancies, we attempted to evaluate cytotoxicity against tumor cells by gammadelta T cells, which were generated from blood cells of patients with myeloma and lymphoma by culturing with zoledronate and a low dose of IL-2. Although gammadelta T cells were expanded in patients with myeloma and lymphoma as well as normal persons, the amplification rates of gammadelta T cells before and after culturing varied from patient to patient in myeloma and lymphoma. gammadelta T cells generated in patients with myeloma and lymphoma showed a potent cytotoxic ability against myeloma/lymphoma cell lines as shown in gammadelta T cells generated in normal subjects. In addition, gammadelta T cells generated in a patient with myeloma showed a cytotoxic ability against self myeloma cells freshly prepared from bone marrow. However, the same gammadelta T cells were demonstrated to be non-cytotoxic to normal cells of the patient. These data demonstrated that gammadelta T cells, which could be expanded in vitro from blood cells of patients with myeloma and lymphoma by culturing with zoledronate and IL-2, possess a sufficient cytotoxic ability against tumor cells. These findings suggested that in vitro generated patients' gammadelta T cells could be applied to gammadelta T cell-mediated immunotherapy for hematological malignancies.
authors.affiliation: Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, 2-746, Asahimachi-dori, 951-8518,Niigata, Japan.
authors.forename: Anri
authors.initials: A
authors.lastname: Saitoh
authors.forename: Miwako
authors.initials: M
authors.lastname: Narita
authors.forename: Norihiro
authors.initials: N
authors.lastname: Watanabe
authors.forename: Nozomi
authors.initials: N
authors.lastname: Tochiki
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Satoh
authors.forename: Jun
authors.initials: J
authors.lastname: Takizawa
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Furukawa
authors.forename: Ken
authors.initials: K
authors.lastname: Toba
authors.forename: Yoshifusa
authors.initials: Y
authors.lastname: Aizawa
authors.forename: Shohji
authors.initials: S
authors.lastname: Shinada
authors.forename: Masuhiro
authors.initials: M
authors.lastname: Takahashi
mesh_terms: D003602:Cytotoxicity, Immunologic; D006801:Humans; D016219:Immunotherapy, Adoptive; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy*; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D016692:Receptors, Antigen, T-Cell, gamma-delta